Ramucirumab in the second-line treatment of metastatic colorectal cancer: a narrative review of literature from clinical trials

Chou-Pin Chen⁴, Tao-Wei Ke², Rebecca Cheng³, Jaw-Yuan Wang⁴,⁵,⁶,⁷

Introduction

Worldwide, colorectal cancer (CRC) was the third most common cancer and the second leading cause of cancer death in 2018, with over 1.8 million new cases reported (1). The global distribution of CRC varies greatly across low to high human development index countries (2), but ~52% of the new cases of CRC reported in 2018 occurred in Asia (1). At diagnosis, 25% of patients have metastatic disease and nearly half of all patients without metastases will develop metastatic CRC (mCRC) (3).

In 2016, CRC accounted for 14.5% of all malignant tumors and for 12.0% of all cancer-related deaths in Taiwan. CRC was the most common cancer in men and the second most common cancer in women (4). Over 15,000 patients are diagnosed with CRC annually, with CRC accounting for 41.9% of all malignancies of the digestive organs and peritoneum in 2016 (4,5). In the same year, 5,722 patients died from a colorectal or anal malignancy, and these tumor types were rated as the third and fourth most common...
causes of cancer-related death in men and women, respectively (4,5).

Goals of treatment for unresectable mCRC include prolonging survival, reducing the impact of tumor-related symptoms and maintaining quality of life (3). Fluoropyrimidines (e.g., capecitabine and fluorouracil) are the cornerstone of conventional palliative chemotherapy and are used in various combinations (3). Common combinations used for first-line therapy in patients with mCRC are fluorouracil plus leucovorin in combination with oxaliplatin (FOLFOX) or irinotecan (FOLFIRI) (3).

The development of new targeted agents has expanded the therapeutic options available for patients with mCRC (5). Both anti-angiogenic drugs targeting the vascular endothelial growth factor (VEGF) pathway and anti-epidermal growth factor receptor (EGFR) monoclonal antibodies have demonstrated antitumor activity when used in combination with conventional chemotherapeutic regimens (6,7).

In line with global clinical guidelines (3), FOLFOX/FOLFIRI and FOLFIRI/FOLFOX can be used interchangeably as first-/second-line therapies in patients with mCRC in Taiwan. Since 2010, the anti-VEGF monoclonal antibody bevacizumab has been reimbursed for the first-line treatment of mCRC in combination with FOLFIRI or fluorouracil/leucovorin (for a maximal cycle of 36 weeks) (8). Most patients with mCRC in Taiwan, especially those with a RAS mutation, are treated with bevacizumab plus FOLFIRI in the first-line setting, with the exception of patients in whom irinotecan is contraindicated.

Several novel targeted agents are also available in the second-line setting. Ramucirumab, a human immunoglobulin G1 (IgG1) monoclonal antibody antagonist of VEGF receptor (VEGFR)-2, demonstrated efficacy in combination with FOLFIRI in the pivotal RAISE trial in patients whose mCRC progressed after bevacizumab plus FOLFOX (7) and has been approved in Taiwan accordingly. The Pan-Asian-adapted European Society for Medical Oncology consensus guidelines recommend ramucirumab plus FOLFIRI as a second-line therapy for the management of patients with mCRC (after first-line oxaliplatin) (9). However, in Taiwan (and other Asian countries such as China and Malaysia), ramucirumab plus FOLFIRI is more commonly used as a third-line or later treatment instead of in the recommended setting, due to lack of reimbursement (10).

Several factors, including patient and tumor characteristics, affect the efficacy of anti-angiogenic drugs and their suitability in certain patient populations (11-15). In this narrative review, we give an overview of overall survival (OS), progression-free survival (PFS) (see Figures 1 and 2, respectively), and tolerability data for ramucirumab in important patient subgroups using data from RAISE and subsequent exploratory studies, and other recent clinical trials and real-world evidence (RWE). Our aim is to summarize the clinical trial literature of second-line ramucirumab in clinically relevant patient subgroups, with a view to illustrating the potential benefit of integrating this regimen into Taiwanese or Asian treatment practice. We present the following article in accordance with the Narrative Review reporting checklist (available at http://dx.doi.org/10.21037/tcr-20-608).

Methods

To identify exploratory and post-hoc analyses of the RAISE clinical trial, a literature search was conducted on MEDLINE (PubMed) using the following search terms “ramucirumab” and “colorectal cancer” and “RAISE”. Only studies investigating the efficacy and safety of ramucirumab in the RAISE study population were included. Another search was conducted to identify other clinical trials, retrospective studies, and case studies not related to the RAISE study using the search terms “ramucirumab” and “colorectal cancer”. No publication date range was set. Review articles, clinical trials in other advanced cancers, and studies of ramucirumab as a first-, fourth-, or higher-line of treatment were excluded. Both searches were conducted on July 1, 2020.

Discussion

RAISE study

In the multicenter, randomized phase III clinical trial, RAISE, ramucirumab plus FOLFIRI was compared with placebo plus FOLFIRI as a second-line treatment for mCRC following first-line FOLFOX-bevacizumab (7). A significant increase in OS was observed in patients in the ramucirumab arm compared with those in the placebo arm [hazard ratio (HR) 0.84, P=0.0219] (7). Patients treated with ramucirumab/FOLFIRI also demonstrated a significant improvement in PFS vs. those treated with placebo/FOLFIRI (P=0.0005) (7).
Figure 1 Forest plot showing overall survival in the general RAISE mCRC population and in patient subgroups. HRs and 95% CIs are shown for subgroups as defined by baseline patient and tumor characteristics (7,12,13,16-19). Patients were grouped into four ramucirumab $C_{\text{min,ss}}$ exposure quartiles: <25% (Q1), 25% to <50% (Q2), 50% to <75% (Q3), and ≥75% (Q4). Potential interactions between treatment-group and subgroup variables were significant at a two-sided $\alpha$ level of 0.10. CEA, carcinoembryonic antigen; CI, confidence interval; $C_{\text{min,ss}}$, minimum steady-state plasma concentration; FOLFIRI, fluorouracil/leucovorin/oxaliplatin; HR, hazard ratio; mCRC, metastatic colorectal cancer; OS, overall survival; PBO, placebo; RAM, ramucirumab; TTP, time to tumor progression; VEGF-D, vascular endothelial growth factor-D.

Figure 2 Forest plot showing progression-free survival in the general RAISE mCRC population and in patient subgroups. HRs and 95% CIs are shown for subgroups as defined by baseline patient and tumor characteristics (7,12,13,16-18). Patients were grouped into four ramucirumab $C_{\text{min,ss}}$ exposure quartiles: <25% (Q1), 25% to <50% (Q2), 50% to <75% (Q3), and ≥75% (Q4). Potential interactions between treatment-group and subgroup variables were significant at a two-sided $\alpha$ level of 0.10. CEA, carcinoembryonic antigen; CI, confidence interval; $C_{\text{min,ss}}$, minimum steady-state plasma concentration; FOLFIRI, fluorouracil/leucovorin/oxaliplatin; HR, hazard ratio; mCRC, metastatic colorectal cancer; PFS, progression-free survival; PBO, placebo; RAM, ramucirumab; TTP, time to tumor progression; VEGF-D, vascular endothelial growth factor-D.
**RAS/BRAF mutation status**

The presence of KRAS mutations have been identified as predictors of resistance to anti-EGFR therapy in patients with mCRC (12,20,21). KRAS exon 2 mutation status was a stratification factor in RAISE; mutant KRAS tumors were present in approximately half of the patient population (12). In wild-type patients, treatment with ramucirumab/FOLFIRI significantly improved OS (P=0.049) and PFS (P=0.004) compared with placebo/FOLFIRI (7,12). These findings were irrespective of post-discontinuation anti-EGFR therapy (12). For patients with mutant KRAS tumors, directional improvements in OS and PFS were seen in the ramucirumab arm vs. the placebo arm (12). Ramucirumab was effective vs. placebo regardless of KRAS mutation status, with no significant interaction between treatment effect and KRAS mutation status for either OS (interaction P=0.505) or PFS (interaction P=0.526) (12).

Recent evidence suggests that other RAS mutations (KRAS exon 3 and 4, NRAS) and BRAF mutations may also reduce the benefit of anti-EGFR therapies (3,21). RAS/BRAF mutation information was available for 85% of the total RAISE population (13). Directional improvements in OS were observed in the ramucirumab arm in all patients compared with the placebo arm (13). Directional improvements for ramucirumab vs. placebo were also observed for PFS in patients with the BRAF mutation. A significant improvement in PFS was seen with ramucirumab over placebo in the RAS mutation subgroup (P=0.021) (13). Treatment-by-mutation status interaction tests indicated that treatment effect did not differ significantly among the three mutation status subgroups for either survival outcome (OS interaction P=0.323; PFS interaction P=0.665) (13).

**Time to tumor progression (TTP) during first-line therapy**

In some cases, the aggressive nature of a disease has been known to impact treatment efficacy adversely, and rapid disease progression can act as a prognostic factor for survival, which may be useful when determining the nature of second-line or later therapy (22). Disease aggression can often be assessed using TTP during first-line therapy (12). Some clinical trials exclude patients with aggressive disease progression; in RAISE, however, patients with TTP <6 or ≥6 months after the initiation of first-line treatment were analysed as prespecified subgroups (12). TTP on first-line therapy was a prognostic factor for patients on second-line therapy (Wald's P<0.0001) (12). No significant differences in OS and PFS were observed between those with TTP <6 months and those with TTP ≥6 months (OS interaction P=0.943; PFS interaction P=0.114) (12).

**Advanced age**

As with any cancer treatment approach, the risk–benefit of a drug must be carefully considered in elderly patients who may be particularly vulnerable to treatment-emergent adverse events (TEAEs) (12,23). In a post-hoc analysis of RAISE study data, ramucirumab/FOLFIRI demonstrated similar trends in OS improvement vs. placebo/FOLFIRI in both patients aged <65 and those aged ≥65 years (12). An improvement in PFS vs. placebo was observed with ramucirumab in both older (P=0.051) and younger patients (P=0.003). However, treatment effect did not differ between the two subgroups (interaction P=0.952 and P=0.697, respectively) (12).

**Tumor sidedness**

Primary tumor location (i.e., left or right colon) has been linked to differences in clinical and biological characteristics between patients and may possibly be predictive of treatment response, particularly for anti-EGFR therapies (14,15). Tumor sidedness was known in 94.4% of the RAISE intention-to-treat population (13). Ramucirumab exhibited a trend for greater efficacy in patients with left-sided CRC than in those with right-sided disease; however, non-significant interaction tests meant that sidedness was not associated with the OS and PFS benefits of ramucirumab therapy (OS interaction P=0.276; PFS interaction P=0.578) (13).

**Baseline carcinoembryonic antigen (CEA) levels**

CEA, a glycoprotein produced by the gastrointestinal tract that can induce tumor angiogenesis, has been seen to increase proportionally with disease progression and may correlate inversely with OS and PFS in patients undergoing first-line therapy (24-26).

In the RAISE study, baseline CEA data were available for 93% of patients (median baseline CEA 34.1 ng/mL). A prespecified subanalysis indicated that baseline CEA (<200 vs. ≥200 µg/L) did not affect the benefit obtained with second-line ramucirumab plus FOLFIRI (6). In a post-hoc study investigating a CEA cutoff of 10 ng/mL...
translational Cancer Research, Vol 9, No 9 September 2020

© Translational Cancer Research. All rights reserved.

Transl Cancer Res 2020;9(9):5645-5654 | http://dx.doi.org/10.21037/tcr-20-608

(based on 2× the upper limit of normal), 29% of patients had CEA levels ≤10 ng/mL at baseline. Ramucirumab/FOLFIRI demonstrated a relatively greater magnitude of improvement in OS and PFS in patients with baseline CEA levels ≤10 mg/mL than in those with CEA levels >10 ng/mL (16). A significant interaction between CEA level and ramucirumab treatment effect was observed for OS at the 0.1 level (interaction P=0.088) but not for PFS (interaction P=0.594); therefore, a prospectively planned study to confirm the predictive role of baseline CEA is needed.

**Baseline VEGF-D levels**

Another prespecified endpoint of the RAISE study was to identify potential predictive biomarkers for the efficacy of ramucirumab (17). Using RAISE study data, Taberner et al. (17) investigated a number of angiogenesis-related mediators as possible predictive factors through an adaptive signature design. Analyses focused on VEGF family members and their receptors, including VEGF-C, VEGF-D, soluble VEGFR-1, VEGFR-2, VEGFR-3 (plasma), and vascular VEGFR-2 (17).

Based on the findings of an exploratory subset analysis, in which only VEGF-D showed a strong association with treatment effect, patients were separated into high and low VEGF-D subgroups (<115 vs. ≥115 pg/mL) (17). In the analyses, involving over 80% of the total RAISE population, high VEGF-D levels were seen in 61% of patients (17). In this high VEGF-D group, median OS (P=0.002) and PFS (P<0.0001) were significantly improved in the ramucirumab arm compared with the placebo arm, respectively (17). In contrast, for the low VEGF-D group, improvements in median OS and PFS were in favor of placebo/FOLFIRI (16). Significant differences in the OS and PFS benefits of ramucirumab were apparent between patients with high and low levels of VEGF-D (interaction P=0.0005 and P<0.0001, respectively) (17). Significantly worse survival outcomes were observed in patients in the high VEGF-D group receiving placebo/FOLFIRI (OS P=0.003) (17). However, these findings were obtained using an assay that was developed for exploratory research purposes. Without a validated assay, this potential predictive factor cannot be utilized for clinical decision making.

**Exposure–response relationship of ramucirumab**

There is a close relationship between the pharmacokinetics of a drug and its efficacy. For many antibody-based anticancer therapies, increasing concentration correlates with an increase in effect (known as the “exposure–response” phenomenon) (27-29). The exposure–response relationship of ramucirumab has been assessed in cancers such as gastric and non-small-cell lung cancer, and findings have indicated a positive relationship between exposure and survival outcomes (30,31).

An exploratory investigation of RAISE data assessed the minimum steady-state plasma concentration (C_{min,ss}) and grouped patients into four ramucirumab C_{min,ss} exposure quartiles: <25% (Q1), 25% to <50% (Q2), 50% to <75% (Q3), and ≥75% (Q4) (18). Approximately 85% of the total RAISE population was included in this analysis. A significant positive association was seen between increasing C_{min,ss} and improved efficacy outcomes with ramucirumab (interaction P=0.0001 for both OS and PFS). This association remained significant after adjustment for factors associated with OS or PFS (18). The two highest ramucirumab exposure groups (Q3 and Q4) demonstrated significantly higher OS than did placebo (P=0.0003 and P=0.003, respectively) (18). Similar results were seen for PFS, with significant improvements seen in Q3 (P=0.0014) and Q4 (P<0.0001) but not in Q1 and Q2 (18).

**Tolerability of ramucirumab**

Ramucirumab has demonstrated acceptable tolerability across numerous clinical trials in other cancers (30,31). In RAISE, most TEAEs were manageable with supportive care or dose modification. Almost one-third (29%) of patients in the ramucirumab arm and 13% of patients in the placebo arm discontinued at least one treatment component (commonly FOLFIRI; only 4% of patients discontinued ramucirumab and 1% discontinued placebo). The incidence of grade ≥3 TEAEs was higher in the ramucirumab arm than in the placebo arm (79% vs. 62%). The most commonly occurring grade ≥3 TEAE was neutropenia (7). In general, the incidence of TEAEs across different patient subgroups were in line with observations from RAISE (7,12,17,18).

As advanced age is often associated with a higher frequency of TEAEs, age–subgroup analyses of RAISE data included not only patients aged <65 and ≥65 years but also an age cutoff of ≥75 years (12). The incidence of TEAEs was generally well-balanced between older (≥75 years) and younger (<75 years) patients. As expected, TEAEs associated with age (e.g., decreased appetite and fatigue) occurred more frequently in older patients; however,
incidence was similar across treatment arms. The incidence of TEAEs of special interest was not increased in patients aged ≥65 vs. ≥75 years (12).

In subgroup analyses based on VEGF-D levels (<115 vs. ≥115 pg/mL), the incidence of TEAEs in both subgroups was similar to that in the overall population from RAISE, although grade ≥3 neutropenia was more frequent in the high VEGF-D group than in the low VEGF-D group (42% vs. 32%, respectively) (7,17).

A post-hoc analysis of RAISE data explored the relationship between OS and treatment-emergent neutropenia (19). Across both treatment arms, rates of neutropenia increased in patients with certain baseline characteristics, including first-line TTP (≥6 months), race (Asian), and sex (female). Median time to the first neutropenic event was 2.6 weeks (3.0 weeks for grade ≥3) in the ramucirumab arm and 3.5 weeks in the placebo arm (3.9 weeks for grade ≥3) (19). In the ramucirumab arm, median OS was significantly longer in patients with neutropenia than in those without neutropenia (16.1 vs. 10.7 months; P=0.0001); corresponding data for the placebo arm were 12.7 vs. 10.7 months (P=0.007) (19). Ramucirumab demonstrated significantly improved OS over placebo in patients with any-grade neutropenia (P=0.020) but not in patients without neutropenia. An interaction between treatment effect and the occurrence of neutropenia was observed for OS (interaction P=0.055). Ramucirumab/FOLFIRI demonstrated similar efficacy in patients with grade ≥2 or ≥3 neutropenia (19).

The relationship between the early incidence of TEAEs and survival outcomes has been explored in a post-hoc analysis of RAISE (32). OS and PFS in patients reporting TEAEs within the first 42 days of receiving ramucirumab/FOLFIRI were assessed. In line with the above-mentioned study (19), neutropenia was associated with improved OS [grade ≤2: HR 0.67, 95% confidence interval (CI): 0.49–0.91; grade ≥3: HR 0.82, 95% CI: 0.64–1.05; P=0.022] but not PFS (grade ≤2: HR 0.85, 95% CI: 0.66–1.10, grade ≥3: HR 1.03, 95% CI: 0.83–1.28; P=0.379). Interestingly, diarrhea was associated with both worse OS (grade ≤2: HR 0.96, 95% CI: 0.76–1.20; grade ≥3: HR 2.72, 95% CI: 1.67–4.44; P=0.001) and PFS (grade ≤2: HR 1.02, 95% CI: 0.83–1.23; grade ≥3: HR 2.22, 95% CI: 1.43–3.45; P=0.005). Similar associations between neutropenia and diarrhea, and survival outcomes were not apparent in the placebo/FOLFIRI group (32).

Other clinical studies

Efficacy data from other recent clinical and real-world studies of second-line treatment ramucirumab in patients with mCRC are summarized in Table 1.

Phase II studies have demonstrated the efficacy of ramucirumab in the second-line therapy of patients with CRC. In one study conducted in 102 patients with KRAS selected wild-type CRC previously treated with FOLFOX or capecitabine/oxaliplatin plus bevacizumab, the addition of ramucirumab to a combination of irinotecan and cetuximab improved PFS significantly vs. the combination alone (33). In another study of 153 patients with mCRC who had progressed on irinotecan-based therapy, median PFS in patients who had received ramucirumab plus modified FOLFOX-6 (mFOLFOX-6) was comparable to that seen in those treated with FOLFOX-6 alone (HR 1.116, 95% CI: 0.713–1.745; P=0.0623) (34).

RWE

Very little RWE for the efficacy of ramucirumab in the second-line treatment of patients with mCRC was identified. In one retrospective study of 43 patients with mCRC across six health centers in Japan, ramucirumab/FOLFIRI as second- or later-line therapy demonstrated a positive impact on survival outcomes, with the median duration of PFS on second-line ramucirumab being equivalent to that seen in RAISE (5.4 months). Patients receiving second-line therapy showed prolonged median OS and PFS compared with patients receiving third- or later-line ramucirumab (35). Another retrospective Japanese study investigated the impact of second-line ramucirumab/FOLFIRI on survival outcomes in 74 patients with mCRC (36). Overall, median PFS and OS were 6.2 and 17.0 months, respectively, findings in line with those from RAISE. Median PFS was somewhat lower in patients who received first-line bevacizumab (5.0 vs. 8.0 months in those not receiving first-line bevacizumab), but this difference did not reach significance (36). Finally, in two case studies from Japan, treatment with ramucirumab/mFOLFOX-6 following first-line treatment with panitumumab/FOLFIRI was beneficial in both patients (both men aged ≥65 years) with mCRC. Tumor shrinkage was noted in one patient (37).

Summary and conclusions

This narrative review of evidence from the large RAISE
| Reference                        | Study design                                                                 | Treatment arms                                                                 | N   | Patient population                                                                 | Findings                                                                                                                                 |
|---------------------------------|------------------------------------------------------------------------------|--------------------------------------------------------------------------------|-----|------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------|
| **Phase II evidence**           |                                                                              |                                                                               |     |                                                                                     |                                                                                                                                           |
| Hochster et al. [2018] (33)     | A randomized phase II trial of IC ± ramucirumab as 2nd-line treatment in patients with mCRC | IC vs. mICR                                                                   | 102 | KRAS selected wild-type patients with advanced and measurable CRC                   | Median PFS: Overall: 5.8 months \[PFS HR: mICR vs. IC: 0.65; \text{P=0.068} \]                                                                 |
| Moore et al. [2016] (34)        | A randomized phase II trial of mFOLFOX-6 plus ramucirumab or icrucumab as a 2nd-line treatment in patients with mCRC | mFOLFOX-6 alone vs. ramucirumab plus mFOLFOX-6 (RAM + mFOLFOX-6) vs. icrucumab plus mFOLFOX-6 (ICR + mFOLFOX-6) | 153 | Patients with mCRC                                                                   | Median PFS: mFOLFOX-6: 18.4 weeks; RAM + mFOLFOX-6: 21.4 weeks; ICR + mFOLFOX-6: 15.9 weeks \[PFS HR: RAM + mFOLFOX-6 vs. mFOLFOX-6: 1.12; P=0.623; ICR + mFOLFOX-6 vs. mFOLFOX-6: 1.60; P=0.044 \]  |
| **Real world evidence**         |                                                                              |                                                                               |     |                                                                                     |                                                                                                                                           |
| Yoshihiro et al. [2019] (35)    | A retrospective analysis of patients with mCRC who received ramucirumab plus FOLFIRI at any therapy line at six healthcare institutions in Japan | Ramucirumab plus FOLFIRI (2nd- vs. ≥3rd-line therapy and high vs. low RDI)     | 43  | Patients with mCRC                                                                   | Median PFS: all patients: 4.8 months; 2nd-line therapy: 5.4 months; ≥3rd-line therapy: 2.8 months; high RDI: 3.2 months; low RDI: 5.7 months \[HR =2.7; \text{P=0.004} \]  |
| Suzuki et al. [2019] (36)       | A retrospective analysis of patients with mCRC who received 2nd-line ramucirumab plus FOLFIRI who were stratified by use of 1st-line bevacizumab | Ramucirumab plus FOLFIRI                                                      | 74  | Patients with mCRC who are bevacizumab-naive or bevacizumab-experienced             | Median PFS: overall: 6.2 months; bevacizumab-naive: 8.0 months; bevacizumab-experienced: 5.0 months \[HR =0.72; P=0.28 \]  |
| Hagino et al. [2017] (37)       | Two case studies of patients with mCRC who received ramucirumab plus FOLFIRI as a 2nd-line treatment | Ramucirumab plus FOLFIRI                                                      | 2   | Older (≥65 years) male patients with mCRC                                           | Treatment with ramucirumab was beneficial and was administered for ≥7 months in both patients. Tumor shrinkage was observed in one patient |

CRC, colorectal cancer; FOLFIRI, fluorouracil/leucovorin/oxaliplatin; FOLFOX, fluorouracil plus leucovorin in combination with oxaliplatin; HR, hazard ratio; IC, irinotecan and cetuximab; mCRC, metastatic colorectal cancer; mFOLFOX, modified FOLFOX; mICR, IC with ramucirumab; N, number of patients; OS, overall survival; PFS, progression-free survival; RDI, relative dose intensity.
phase III clinical trial (7), its exploratory studies (12,16,18), as well as data from other clinical trials (33,34) and RWE (35-37) has shown that ramucirumab has consistent efficacy across multiple patient subpopulations and can prolong patient survival when administered as part of second-line therapy for mCRC. Although the results of exploratory and retrospective studies (conducted in non-randomized populations) should be treated with caution, those reviewed here provide important information that can be used to help identify patient subgroups that will potentially benefit from treatment with ramucirumab, and to indicate areas for further research.

Recently, reimbursement guidelines in Taiwan have been revised, effective at the beginning of 2019 (38), to allow bevacizumab to be combined with either irinotecan (FOLFIRI)- or oxaliplatin (FOLFOX)-based chemotherapy. A recent observational study from Taiwan reported PFS to be higher in patients who had received second-line treatment with bevacizumab/aflibercept plus FOLFOX-6 vs. FOLFOX-6 alone (39). The reimbursement of other anti-angiogenic drugs on the basis of demonstrated efficacy increases the possibility of using ramucirumab with FOLFIRI in the second-line setting. However, lack of reimbursement for ramucirumab strongly limits its use in clinical practice in Taiwan and other Asian countries.

Acknowledgments

The authors would like to thank Dr. Elinor Wylde and Gill Gummer (Rx Communications, Mold, UK) for medical writing assistance with the preparation of this article, funded by Eli Lilly and Company.

Funding: This work was funded by Eli Lilly and Company. One of the authors, involved in the conception of this review, is an employee of Eli Lilly and Company.

Footnote

Reporting Checklist: The authors have completed the Narrative Review reporting checklist. Available at http://dx.doi.org/10.21037/tcr-20-608

Peer Review File: Available at http://dx.doi.org/10.21037/tcr-20-608

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/tcr-20-608). Dr. Cheng reports personal fees from Eli Lilly and Company, during the conduct of the study. Dr. Cheng is an employee of Eli Lilly and Company. The other authors have no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the formal work is properly cited (including links to both the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.

References

1. The Global Cancer Observatory. Colorectal cancer fact sheet 2018. Available online: http://gco.iarc.fr/today/data/factsheets/cancers/10_8_9-Colorectum-fact-sheet.pdf (Accessed 24 December 2018).
2. Arnold M, Sierra MS, Laversanne M, et al. Global patterns and trends in colorectal cancer incidence and mortality. Gut 2017;66:683-91.
3. Van Cutsem E, Cervantes A, Nordlinger B, Arnold D; ESMO Guidelines Working Group. Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2014;25 Suppl 3:iii1-9. Erratum in: Ann Oncol 2015;26 Suppl 5:v174-7.
4. Health Promotion Administration, Ministry of Health and Welfare. Cancer Registry Annual Report 2016, Taiwan. Available online: https://www.hpa.gov.tw/Pages/Detail.aspx?nodeid=269&pid=10227 (Accessed 18 January 2019).
5. Health Statistics. Ministry of Health and Welfare. Statistics of General Health and Welfare 2018, Taiwan. Available online: https://www.mohw.gov.tw/lp-4614-2.html (Accessed 16 December 2019).
6. Foubert F, Matysiak-Budnik T, Touchefeu Y. Options for metastatic colorectal cancer beyond the second line of treatment. Dig Liver Dis 2014;46:105-12.
7. Tabernero J, Yoshino T, Cohn AL, et al. RAISE Study Investigators. Ramucirumab vs. placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after
first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. Lancet Oncol 2015;16:499-508.

8. National Health Insurance, Drug Payment Regulations Amendment Checklist, 2017, Taiwan. Available online: https://www.nhi.gov.tw/Resource/bulletin/6917_1060053987-1.pdf (Accessed 7 February 2019).

9. Yoshino T, Arnold D, Taniguchi H, et al. Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO–ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS. Ann Oncol 2018;29:44-70.

10. Taiwan Food and Drug Administration, Ministry of Health and Welfare. 2015. Available online: https://www.fda.gov.tw/MLMS/H0001D.aspx?Type=Lic&LicId=60000999 (Accessed 7 February 2019).

11. De Stefano A, Carlomagno C. Beyond KRAS: Predictive factors of the efficacy of anti-EGFR monoclonal antibodies in the treatment of metastatic colorectal cancer. World J Gastroenterol 2014;20:9732-43.

12. Obermannová R, Van Cutsem E, Yoshino T, et al. Subgroup analysis in RAISE: a randomized, double-blind phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab or placebo in patients with metastatic colorectal carcinoma progression. Ann Oncol 2016;27:2082-90.

13. Yoshino T, Portnoy DC, Obermannová R, et al. Biomarker analysis beyond angiogenesis: RAS/RAF mutation status, tumour sidedness, and second-line ramucirumab efficacy in patients with metastatic colorectal carcinoma from RAISE—a global phase III study. Ann Oncol 2019;30:124-31.

14. Lee GH, Malietzis G, Askari A, et al. Is right-side colon cancer different to left-side colorectal cancer? A systematic review. Eur J Surg Oncol 2015;41:300-8.

15. Schrag D, Weng S, Brooks G, et al. The relationship between primary tumor sidedness and prognosis in colorectal cancer. J Clin Oncol 2016;34:abstr 3505.

16. Yoshino T, Obermannová R, Bodoky G, et al. Baseline carcinoembryonic antigen as a predictive factor of ramucirumab efficacy in RAISE, a second-line metastatic colorectal carcinoma phase III trial. Eur J Cancer 2017;78:61-9.

17. Tabernerio J, Hozak RR, Yoshino T, et al. Analysis of angiogenesis biomarkers for ramucirumab efficacy in patients with metastatic colorectal cancer from RAISE, a global, randomized, double-blind, phase III study. Ann Oncol 2018;29:602-9.

18. Cohn AL, Yoshino T, Heinemann V, et al. Exposure-response relationship of ramucirumab in patients with advanced second-line colorectal cancer: exploratory analysis of the RAISE trial. Cancer Chemother Pharmacol 2017;80:599-608.

19. Grothey A, Yoshino T, Bodoky G, et al. Association of baseline absolute neutrophil counts and survival in patients with metastatic colorectal cancer treated with second-line antiangiogenic therapies: exploratory analyses of the RAISE trial and validation in an electronic medical record data set. ESMO Open 2018;3:e000347.

20. Perincheri S, Hui P. KRAS mutation testing in clinical practice. Expert Rev Mol Diagn 2015;15:375-84.

21. Yen LC, Uen YH, Wu DC, et al. Activating KRAS mutations and overexpression of epidermal growth factor receptor as independent predictors in metastatic colorectal cancer patients treated with cetuximab. Ann Surg 2010;251:254-60.

22. Shihiura K, Matsuo K, Yokota T, et al. Prognostic factors for metastatic colorectal cancer patients undergoing irinotecan-based second-line chemotherapy. Gastrointest Cancer Res 2011;4:168-72.

23. Kuboki Y, Mizunuma N, Ozaka M, et al. Grade 3/4 neutropenia is a limiting factor in second-line FOLFIRI following FOLFOX4 failure in elderly patients with metastatic colorectal cancer. Oncol Lett 2011;2:493-8.

24. Fakih MG, Padmanabhan A. CEA monitoring in colorectal cancer. What you should know. Oncology (Williston Park) 2006;20:579-87; discussion 588, 594, 596 passim.

25. Prager GW, Braemswig KH, Martel A, et al. Baseline carcinoembryonic antigen (CEA) serum levels predict bevacizumab-based treatment response in metastatic colorectal cancer. Cancer Sci 2014;105:996-1001.

26. Michl M, Stintzing S, Fischer von Weikersthal L, et al. FIRE-3 Study Group. CEA monitoring in colorectal cancer. What you should know. Oncology (Williston Park) 2006;20:579-87; discussion 588, 594, 596 passim.

27. Feng Y, Roy A, Masson E, et al. Exposure-response relationships of the efficacy and safety of ipilimumab in patients with advanced melanoma. Clin Cancer Res 2013;19:3977-86.

28. Wang J, Song P, Schrieber S, et al. Exposure-response relationship of T-DM1: insight into dose optimization for patients with HER2-positive metastatic breast cancer. Clin Pharmacol Ther 2014;95:558-64.

29. Zhu M, Tang R, Doshi S, et al. Exposure-response analysis
of rilotumumab in gastric cancer: the role of tumour MET expression. Br J Cancer 2015;112:429-37.
30. Tabernero J, Ohtsu A, Muro K, et al. Exposure-response analyses of ramucirumab from two randomized, phase III trials of second-line treatment for advanced gastric or gastroesophageal junction cancer. Mol Cancer Ther 2017;16:2215-22.
31. Smit EF, Garon EB, Reck M, et al. Exposure-response relationship for ramucirumab from the randomized, double-blind, phase 3 REVEL trial (docetaxel vs. docetaxel plus ramucirumab) in second-line treatment of metastatic non-small cell lung cancer. Cancer Chemother Pharmacol 2018;82:77-86.
32. Lim HH, Hopkins AM, Rowland A, et al. Effect of early adverse events on survival outcomes of patients with metastatic colorectal cancer treated with ramucirumab. Target Oncol 2019;14:743-8
33. Hochster H, Catalano P, O’Dwyer P, et al. Randomized trial of irinotecan and cetuximab (IC) vs. irinotecan, cetuximab and ramucirumab (ICR) as 2nd line therapy of advanced colorectal cancer (CRC) following oxaliplatin and bevacizumb based therapy: Result of E7208. J Clin Oncol 2018;36:abstr 3504.
34. Moore M, Gill S, Asmis T, et al. Randomized phase II study of modified FOLFOX-6 in combination with ramucirumab or icrucumab as second-line therapy in patients with metastatic colorectal cancer after disease progression on first-line irinotecan-based therapy. Ann Oncol 2016;27:2216-24.
35. Yoshihiro T, Kusaba H, Makiyama A, et al. Efficacy and safety of ramucirumab plus modified FOLFIRI for metastatic colorectal cancer. Int J Clin Oncol 2019;24:508-15.
36. Suzuki T, Shinozaki E, Osumi H, et al. Second-line FOLFIRI plus ramucirumab with or without prior bevacizumab for patients with metastatic colorectal cancer. Cancer Chemother Pharmacol 2019;84:307-13.
37. Hagino S, Miyata T, Sakamoto K. Experience of ramucirumab plus FOLFIRI as second-line treatment for metastatic colorectal cancer in our hospital. Gan To Kagaku Ryoho 2017;44:1559-61.
38. Health Agency Announcement: Amendment of Payment Rules for Bevacizumab-containing Drugs 2019. Available online: http://www.tsim.org.tw/helth/hel328_m710.html (Accessed 16 December 2019).
39. Tsai HL, Huang CW, Ma CJ, et al. An observational study of vascular endothelial growth factor inhibitors as second-line treatment for metastatic colorectal cancer treated with bevacizumab plus FOLFIRI beyond progression: the association with RAS mutation and tumor sidedness. Transl Cancer Res 2019;8:2357-70.

Cite this article as: Chen CP, Ke TW, Cheng R, Wang JY. Ramucirumab in the second-line treatment of metastatic colorectal cancer: a narrative review of literature from clinical trials. Transl Cancer Res 2020;9(9):5645-5654. doi: 10.21037/tcr-20-608